AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01874392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational inhaled insulin (Technosphere)
Description: by MannKind Corp. IND 61,729
Study NCT01874392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas (AP) device (APS©)
Description: Device includes:~* OneTouch® Ping® Glucose Management System with modified Meter-Remote from Animas® Corp or the OmniPod® Insulin Management System from Insulet Corp.~* Dexcom® G4® CGM System (CGM) from Dexcom® Corp~* Control algorithm: zone-Model Predictive Control (zone-MPC) with safety Health Monitoring System (HMS)
Study NCT03692403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinagolide 360 µg
Description: Vaginal ring containing quinagolide 360 µg for daily releases
Study NCT03692403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinagolide 720 µg
Description: Vaginal ring containing quinagolide 720 µg for daily releases
Study NCT03692403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinagolide 1080 µg
Description: Vaginal ring containing quinagolide 1080 µg for daily releases
Study NCT03692403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT02030132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback compared to 75th percentile
Study NCT03584360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone-Calcipotriene Topical
Description: Comparison between betamethasone-calcipotriol and betamethasone
Study NCT03584360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone-Calcipotriene Topical
Description: Comparison between betamethasone-calcipotriol and propionate de clobetasol
Study NCT00726986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Study NCT00726986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Study NCT00726986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Oral sorafenib tosylate twice daily beginning on day 1 of course 1 and continuing for up to 1 year in the absence of disease progression or unacceptable toxicity.
Study NCT02687633 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: JASPER
Description: JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari and Dr. Amanda Gulsrud at UCLA. It targets the foundations of social communication (joint attention, imitation, play) and uses naturalistic strategies to increase the rate and complexity of social communication.
Study NCT02687633 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JASPER
Description: JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari and Dr. Amanda Gulsrud at UCLA. It targets the foundations of social communication (joint attention, imitation, play) and uses naturalistic strategies to increase the rate and complexity of social communication.
Study NCT01313793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A-B
Description: Subjects to receive 3 X 15 mg tablets of the clinical formulation in first period then 1 x 45 mg tablet of the commericializable formulation in 2nd period.
Study NCT01313793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B-A
Description: Subjects to receive 1 x 45 mg tablet of the commericializable formulation in first period then 3X 15 mg tablets of the clinical formulation in 2nd period.
Study NCT04438252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CariScan Pro
Description: Device for early caries detection
Study NCT04438252 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Digital Radiograpgy
Description: Device for digital x-ray imaging
Study NCT00778986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: heart failure remote patient monitoring system
Description: remote monitoring of weight, blood pressure, ECG, and symptoms
Study NCT01900756 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: THRIVES
Description: Pre-appointment phone text In-clinic educational video Patient report card Post-clinic phone text Outpatient stroke registry
Study NCT03550638 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coil system(Ton-bridgeMT)
Description: 1. It consists of a push system with a development mark, and a Detachable platinum-tungsten alloy coil which is connected to the push system. It can be used for embolization of intracranial aneurysms, and other neurovascular abnormalities, such as arteriovenous malformation and arteriovenous fistula.
Study NCT03550638 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Axium Detachable Coil(Medtronic)
Description: 2. It is made up of a push system with a development mark, a platinum-tungsten alloy embolized coil connected to the push system and a manual release device for releasing the coil from the distal end of the push system. It is mainly used for embolization of intracranial aneurysms, and other neurovascular abnormalities, such as arteriovenous malformation and arteriovenous fistula.
Study NCT02030132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forgiveness
Study NCT02030132 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial Incentive
Description: For the first three months of the study, a weekly lottery will be held. Teams whose average daily step count for that week is ≥ 7000 will be eligible to collect their lottery winnings. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.
Study NCT00164736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maternal zidovudine/lamivudine/lopinavir-ritonavir
Description: Total daily dose: zidovudine 600mg, lamivudine 300mg, (taken as Combivir 1 tab twice a day with food). Lopinavir/ritonavir 400/100mg (taken as 2 tabs twice a day). Commencing after delivery and through to 28 weeks.
Study NCT00164736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infant nevirapine
Description: Nevirapine suspension once daily dose. 0-14days: 10mg; 3-18weeks: 20mg; 19-28weeks: 30mg.~To 28 weeks while breastfeeding.
Study NCT00164736 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Maternal protein and calorie supplement
Description: High energy, nutrient-dense, micronutrient fortified nutritional supplement. Daily: Energy 700kcal, Protein 20g, 100% of recommended dietary allowance for all micronutrients during the 6 months of lactation. Vitamin A is excluded.
Study NCT03624218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy
Description: Using a combination of In vivo and Imaginal exposure, Prolonged Exposure therapy aims to treat those with Posttraumatic Stress Disorder.
Study NCT04172909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LEGO Bricks MRI
Description: LEGO Bricks model MRI (A model of the MRI machine and adjacent control room made out of LEGO bricks) will be used by the child life specialist to prepare the child for MRI
Study NCT04172909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mock MRI tube
Description: Mock MRI tube will be used by the child life specialist to prepare the child for MRI
Study NCT05454930 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Filtered Air
Description: The vehicle is fitted with a (High-Efficiency Particulate Absorbing, HEPA) filter device incorporating a charcoal filter, as well as an augmented cabin filter
Study NCT03203954 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Learning
Description: Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
Study NCT02030132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: For the first three months of the study, a weekly lottery will be held. Teams whose average daily step count for that week is ≥ 7000 will be eligible to collect their lottery winnings. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.
Study NCT03203954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Learning: Instructed statistics
Description: Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
Study NCT03203954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Learning: Changing statistics
Description: Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
Study NCT04440319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Intervention group is individual with T2DM who will receive DM Nutrition education for 3 months. There are 75 subjects in Intervention group at 2 districts and 4 Public Health Care (PHC).
Study NCT03567941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocodon bitartrate-acetaminophen arm 2
Description: Tablet orally administered under fed conditions
Study NCT02275598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: 1.8 mg/kg, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: 2
Study NCT02275598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABVD
Description: Doxorubicin 25 mg/m2 IV, Bleomycin 10,000 units/m2 IV, Vinblastine 6 mg/m2 IV, Dacarbazine 375 mg/m2 IV on days 1-15 of each 28 day cycle. Number of Cycles: 3 or 6 according to initial disease stage.
Study NCT03170557 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional chinese acupuncture
Description: Traditional chinese acupuncture (somatopuncture points, auriculotherapy points, craniopuncture and wrist-ankle acupuncture). Simultaneously, the usual pharmacological treatment for pain is maintained, based on clinical needs.
Study NCT03170557 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Aspecific needle skin stimulation
Description: Superficial needling of needles in skin areas outside the pain affected dermatome(s). Simultaneously, the usual pharmacological treatment for pain is maintained, based on clinical needs.
Study NCT00493974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zileuton
Description: Zyflo tablets, 600 mg, 4 times a day
Study NCT00493974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 4 x daily
Study NCT02766790 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: TA-65MD
Description: TA-65, a purified small molecule extracted from Astragalus root
Study NCT02766790 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, an inactive formulation
Study NCT03345433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interactive group drumming sessions
Description: interactive group drumming sessions
Study NCT01244191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Tivantinib 720 mg daily as 3 x 120 mg oral tablets given twice a day
Study NCT01244191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Tivantinib Placebo tablets given twice a day
Study NCT01244191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib 150 mg oral tablets, given once a day
Study NCT01244191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg oral tablets, given once a day
Study NCT02921763 — intervention group
Intervention type: DRUG
Intervention: Dydrogesterone
Study NCT04609995 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Incentives
Description: No financial incentive
Study NCT00845546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets
Study NCT00845546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets
Study NCT00642018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Docetaxel 75 milligrams per square meter (mg/m²) intravenously on Day 1 of a 21-day cycle. Patients may receive up to 10 cycles of study therapy or until progressive disease. Additional cycles may be approved by sponsor as long as the patient is benefitting from therapy.
Study NCT00642018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel 75 milligrams per square meter (mg/m²) intravenously on Day 1 of a 21-day cycle. Patients may receive up to 10 cycles of study therapy or until progressive disease. Additional cycles may be approved by sponsor as long as the patient is benefitting from therapy.
Study NCT00642018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2181308 sodium
Description: LY2181308 sodium (referred to as LY2181308 throughout this record) administered weekly plus docetaxel 75 mg/m² intravenously administered every 21 days. Patients may receive up to 10 cycles of study therapy or until progressive disease. Additional cycles may be approved by sponsor as long as the patient is benefitting from therapy.
Study NCT03567941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodon bitartrate-acetaminophen arm 2
Description: Tablet orally administered under fed conditions
Study NCT00642018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 5 mg given orally twice daily continuously while receiving docetaxel therapy
Study NCT00642018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 5 mg given orally twice daily continuously while receiving docetaxel therapy
Study NCT04312438 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: oral food challenge with cow's milk proteins
Description: in children with diagnosed Cow's Milk Allergy open oral food challenge test with cow's milk protein (milk formula in children up to 3 yo, cow,s milk after 3 yo) will be carried out
Study NCT02833376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: alcohol antisepsis
Study NCT02833376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chlorhexidine antisepsis
Study NCT04244201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaporous Hyperoxia Therapy
Description: 1 hour of treatment, 4 times per week
Study NCT02050425 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-CPAP device
Description: short-term CPAP withdrawal by the use of Placebo-CPAP
Study NCT02050425 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Patients continue therapeutic CPAP therapy
Study NCT02681224 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TR987 Gel with Silon Bandage
Description: Novel healing gel with occlusive dressing
Study NCT02681224 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TR987 without Silon Bandage
Description: Novel healing gel without occlusive dressing
Study NCT02681224 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel with Silon Bandage
Description: Placebo gel with occlusive dressing
Study NCT02681224 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel without Silon Bandage
Description: Placebo Gel without occlusive dressing
Study NCT02540317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based CBT
Description: Internet-based treatment with therapist support using an asynchronous messaging system. The treatment is comprised of 12 modules (similar to chapters) and the treatment is 12 weeks long. The treatment is based on cognitive behavior therapy
Study NCT04327856 — intervention group
Intervention type: PROCEDURE
Intervention: Cataract Surgery
Description: The cataract will be removed from patient's eye and artificial intraocular lens will be implanted
Study NCT01530763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Description: Treatment Group 1:~Drug: Ceftaroline fosamil Children ≥ 6 months: IV ceftaroline fosamil 12 mg/kg for subjects weighing ≤ 33 kg or 400 mg for subjects weighing > 33 kg will be infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)~Children \< 6 months: Ceftaroline fosamil 8 mg/kg over 60 (± 10) minutes q8h (± 1 hour)
Study NCT01530763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: Treatment group 2:~75 mg/kg/day up to 4 g/day IV in equally divided doses, each infused over 30 (± 10) minutes q12hr (± 2 hours)
Study NCT03567941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference
Description: Tablet orally administered under fasted conditions
Study NCT03567941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Reference
Description: Tablet orally administered under fasted conditions
Study NCT03567941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference
Description: Tablet orally administered under fasted conditions
Study NCT01307267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05082566
Description: Intravenous, Dose escalation, once per month
Study NCT01307267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Intravenous, 375 mg/m2, once per week for 4 weeks
Study NCT01307267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05082566
Description: IV, Dose escalation, once per month
Study NCT01183936 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2-cm margin
Description: Patients with CMM treated with a surgical safety margin of 2-cm in the surrounding skin and down to the fascia.
Study NCT01530763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin clavulanate
Description: Oral Switch for Treatment Groups 1 and 2:~PO amoxicillin clavulanate 90 mg/kg/day divided q12h in subjects with infections due to susceptible organisms on or after Study Day 4 (a minimum of 7 IV doses required if randomized to ceftaroline.)
Study NCT01530763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin clavulanate
Description: Oral Switch for Treatment Groups 1 and 2:~PO amoxicillin clavulanate 90 mg/kg/day divided q12h in subjects with infections due to susceptible organisms on or after Study Day 4 (a minimum of 7 IV doses required if randomized to ceftaroline.)
Study NCT01939925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New plain language summary format
Description: New plain language summary includes qualitative and quantitative description of text (absolute effects and natural frequencies provided); quantitative results provided in a table; quality of the evidence according to GRADE provided in a table; question and answer format; follows principles of linguistic frameworks (e.g. progressive movements from introduction to 'bottom line')
Study NCT01939925 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current plain language summary format
Description: Current plain language summary includes qualitative description of effects only; inconsistent description of the quality of the evidence; paragraph of text; inconsistent flow of information
Study NCT03764436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LEAPS-NCHD Program
Description: The LEAPS-NCHD program trains young women aged 18 - 24 years with a minimum of 10 years of basic education to be preschool teachers, or Community Youth Leaders (CYLs) in community-based preschools in rural Sindh. CYLs will receive two weeks of classroom-based basic-training and 6 months of on-the-job coaching and support. A maximum of 20 children aged 3.5 -5 years old will be enrolled in each preschool. One preschool will be opened per cluster (village). Children will receive a minimum of 6 months of program exposure between assessment rounds.
Study NCT01183936 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 4-cm margin
Description: Patients with CMM treated with a surgical safety margin of 4-cm in the surrounding skin and down to the fascia.
Study NCT04592575 — intervention group
Intervention type: OTHER
Intervention: Vestibular Evaluation
Description: Each patient will have a full vestibular evaluation by a physical therapist
Study NCT04700189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ab interno canaloplasty
Description: A modification of traditional canaloplasty procedure. Can be combined with or done without cataract surgery.
Study NCT04066725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Description: Participants will be given ASA 81 mg orally once daily for a total of 60 days
Study NCT04066725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 325mg
Description: Participants will be given ASA 325 mg orally once daily for a total of 60 days
Study NCT04066725 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Participants will be given placebo orally once daily for a total of 60 days